Clinical Trials Logo

Clinical Trial Summary

The Re-Shape CV-Risk Study is a clinical study where renal adrenergic denervation (RDN) is done in high risk patients with treatment-resistant hypertension. RDN is a mini-invasive, percutaneous technique where an ablation catheter is inserted through a femoral artery into the renal arteries, for destruction of the adrenergic nerve bundles in the artery adventitia by means of radio-frequency ablation. RDN leads to sympathetic denervation of the kidneys, which in the "Symplicity trials" led to an impressive reduction of blood pressure (- 33 /-11 mmHg). In a pilot study, where 40 % of the patients had diabetes, RDN seemed to have beneficial effects not only on blood pressure, but also on insulin sensitivity and hyperinsulinaemia.

The investigators aim to introduce RDN as a clinical study where blood pressure reduction and methodical, technical aspects will be evaluated, but more importantly, also additional effects of RDN on sub-clinical organ damage (endothelial function, vascular stiffness, fundus-, heart-, kidney injury), quality of life, arrhythmia, and glucose metabolism. The investigators hypothesis is that RDN will have positive effect on glucose metabolism, QOL and sub-clinical organ damage.


Clinical Trial Description

n/a


Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms


NCT number NCT01630928
Study type Interventional
Source University Hospital of North Norway
Contact
Status Completed
Phase N/A
Start date March 2013
Completion date December 2015

See also
  Status Clinical Trial Phase
Recruiting NCT02385864 - CPAP Effect on Blood Pressure and Arterial Stiffness in Obstructive Sleep Apnea Patients With Resistant Hypertension N/A
Completed NCT01833429 - Autonomic Dysfunction in Resistant Hypertension N/A
Completed NCT02426099 - Efficacy of Spironolactone in Cameroonian Diabetic Patients With Resistant Hypertension Phase 4
Recruiting NCT02623036 - The Use of Ambulatory Blood Pressure Monitors to Assess Angiotensin Converting Enzyme Inhibitors Phase 1
Completed NCT02587533 - Peripheral Chemoreflex/Arterial Baroreflex Interaction in Patients With Electrical Carotid Sinus Stimulation N/A
Recruiting NCT01863082 - Resistant Hypertension and Physical Activity Performed in a Heated Pool N/A
Terminated NCT03730519 - UK Registry for Baroreflex Activation Therapy N/A
Active, not recruiting NCT05017935 - RADIANCE Continued Access Protocol N/A
Completed NCT01520506 - Rapid Renal Sympathetic Denervation for Resistant Hypertension N/A
Active, not recruiting NCT02369081 - Optimum Treatment for Drug-Resistant Hypertension Phase 4
Withdrawn NCT04542681 - MANP in African Americans With Hypertension Phase 1
Completed NCT05395403 - Use of Automated Office Blood Pressure Monitoring N/A
Recruiting NCT02057783 - Physical Activity Program for Reducing Blood Pressure in Sleep Apnea Patients With Resistant Hypertension N/A
Completed NCT01848275 - Full Length Versus Proximal Renal Arteries Ablation N/A
Completed NCT01062763 - The Effect of Spironolactone on Blood Pressure in Type-2 Diabetics With Resistant Hypertension Phase 3
Completed NCT01834118 - Reintervention-study After Previous Renal Denervation in Non-responding Patients With Severe Hypertension N/A
Active, not recruiting NCT01703780 - The Diagnosis and Treatment of Resistant Hypertension, the Prevalence and the Prognosis N/A
Not yet recruiting NCT02042066 - Safety and Efficacy Study of Extracorporeal Shockwave Therapy in the Treatment of Patients With Resistant Hypertension Phase 1
Completed NCT02667912 - Distal Renal Denervation N/A
Recruiting NCT00994617 - Monotherapy Versus Dual Therapy for Initial Treatment for Hypertension Phase 4